MedTrace Logo

Study of South African Dialysis Patients

NCT01890577 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2016-07-12

Study results available
· View outcomes & findings →

Summary

An observational study to describe the treatment of anaemia in patients with chronic kidney disease, who are receiving dialysis treatment at selected study centres in South Africa.

Conditions

  • Chronic Kidney Disease, Receiving Dialysis

Interventions

DRUG

Aranesp

Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890577 on ClinicalTrials.gov